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KRE1Abstract Bioﬁlm formation is often associated with increased Candida resistance toward anti-
fungal agents. Therefore, the current study aimed to assess the incidence of bioﬁlm formation
among Candida isolates and to investigate the effect of high doses of ﬂuconazole {FLC}, voriconaz-
ole {VOC} and amphotericin B {AMB}, singly and in combination on mature bioﬁlms. Moreover,
it aimed to assess the expression of selected genes (CDR1, KRE1 and SKN1) responsible for
Candida bioﬁlm resistance. The study included 49 patients; samples were collected from the King
Khalid Hospital, Riyadh, Saudi Arabia. Isolates were prepared for bioﬁlm formation and quanti-
ﬁcation using 0.4% (w/v) crystal violet. Minimum Inhibitory concentration (MIC) and fractional
inhibitory concentration (FIC) were conducted by the broth microdilution method. Bioﬁlm eradi-
cation was evaluated using counting, XTT stain intensity and observed under the inverted micro-
scope. Selected genes were evaluated in Candida bioﬁlms under the effect of antifungal exposure
using QPCR. The major isolates were Candida albicans (65.3%) followed by Candida tropicalis
and Candida glabrata. 77.6% of the strains were bioﬁlm formers. AMB showed susceptibility in
56 N.H. Ibrahim et al.87.8% of isolates, followed by VOC (77.6%) and FLC (67.3%). MIC50 and MIC90 were (0.03,
0.125), (0.5, 8), (2, >128) lg/ml for AMB, VOC and FLC, respectively. 34.7% and 18.4% of
the isolates were antagonistic to AMB/FLC and AMB/VOC, respectively. Mature bioﬁlms of ten
selected isolates were found resistant to FLC (1000 lg/ml). VOR and AMB concentration required
to inhibit bioﬁlm formation was 16–250 fold higher than the MIC for planktonic cells. Isolates
showed signiﬁcant reduction with antifungal combination when compared with the untreated con-
trols (p value 6 0.01), or using ﬂuconazole alone (p value 6 0.05). High doses of the antifungals
were employed to assess the effect on the persisters’ selected gene expression. Marked over expres-
sion of SKN1 and to a lesser extent KRE1 was noticed among the mature bioﬁlms treated with
AMB alone or in combination after 1 h of exposure, and SKN1 expression was even more sharply
induced after 24 h. No statistically signiﬁcant over expression of CDR1 was observed in bioﬁlms
after exposure to high doses of FLC, VOC or any of the combinations used.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Candida species are themost common cause of fungal infections.
Candida induced infections range from non-life-threatening
mucocutaneous illnesses to invasive processes that may involve
virtually any organ. The growing frequency of hospital acquired
Candida especially bloodstream infections is due to the increased
use of immunosuppressive therapy in cancer and transplant
patients, which leads to breakdown of the barrier between the
gut and bloodstream (Nucci and Anaissie, 2001).
Candida cells, as proven in many studies, are able to adhere
to and colonize surfaces of medical devices, such as central
venous catheters, orthopedic prostheses, intrauterine devices
and prosthetic joints and valves, among others, resulting in
the development of a bioﬁlm (Douglas and Cobbs, 1992; Raad
et al., 1993; Tunney et al., 1999). Infections due to the presence
of fungal bioﬁlms are a major clinical concern as these struc-
tures are characterized by increased resistance to antifungal
therapy (Ramage et al., 2006).
Various antifungal agents are used to treat these infections,
including azoles and polyenes (Pappas et al., 2004). Fluconazole
(FLC) as well as voriconazole (VOC), approved in 2002, belong
to the tiazoles, they interfere with ergosterol biosynthesis by
binding to lanosterol 14-a demethylase (Richardson, 1990).
The latter enzyme is crucial for ergosterol production, and inhi-
bition of its activity which causes disruption of the cell mem-
brane leading to growth inhibition of the fungus (Kelly et al.,
1993). Amphotericin B (AMB) is a member of the polyene
family (Warnock, 1991). This molecule binds to ergosterol and
forms pores resulting in a disorganizedmembrane with increased
permeability. In addition, AMB induces cell damage by generat-
ing lethal reactive oxygen species (Brajtburg et al., 1990).
The progression of drug resistance within Candida bioﬁlms
has been associated with a parallel increase in the maturation
process (Sardi et al., 2011). Furthermore, some studies have
shown that bioﬁlms of Candida develop statically in the pres-
ence of a minimal matrix and exhibit the same level of resis-
tance to antifungal treatment; as cells grown in shaker and
exhibiting large amounts of matrix (Seneviratne et al., 2008;
Sardi et al., 2011). However, several molecular mechanisms
of resistance to antifungal agents in Candida have been de-
scribed. In particular, these include the increased efﬂux of anti-
fungal agents due to the overexpression of efﬂux genes, CDR1
and CDR2 (the family of ABC membrane transport proteins –
the ATP binding cassette) (Sardi et al., 2011). Moreover,changes in b-1,6-glucan biosynthesis have also been proposed
as a resistance mechanism against AMB (Gale, 1986). SKN1
and KRE1, two genes involved in b-1,6-glucan biosynthesis
(Mio et al., 1997), were found to be differentially expressed after
in vitro exposure to antifungal treatment (Liu et al., 2005).
A combined action of different mechanisms is believed to
contribute to increased resistance, especially in the presence
of persisters in the bioﬁlm, which are able to tolerate high con-
centrations of antimycotics (Seneviratne et al., 2008). Interest-
ingly, these persisters are not mutants but rather phenotypical
variants of wild type cells (LaFleur et al., 2006). Until now, the
molecular basis of persistence in Candida species bioﬁlms is not
fully understood (Lewis, 2010).
Most of the published studies examining the transcriptional
expression of drug-resistance genes in Candida spp. have been
conﬁned to the planktonic mode of growth, and few data are
available for the bioﬁlm mode (Sanglard et al., 1995; White,
1997; Lopez-Ribot et al., 1998; Franz et al., 1998, 1999; Perea
et al., 2001; Holmes et al., 2008). Therefore, the current study
aimed to assess the incidence of bioﬁlm formation among Can-
dida clinical isolates and to investigate the effect of high doses
of commonly used antifungal drugs (ﬂuconazole, voriconazole
and amphotericin B, singly and in combination) on Candida
mature (48 h) bioﬁlms. Moreover, it aimed to assess the
expression of selected genes (CDR1, KRE1 and SKN1) of
those known to be responsible for resistance in Candida bio-
ﬁlms under the effect of antifungal exposure.2. Subjects and methods
2.1. Fungal isolates
The current study included 49 Candida isolates; they were col-
lected from the Microbiology Laboratory, King Khalid Hospi-
tal, KSU, Riyadh, SA, between December 2010 and May 2012
from various clinical samples. Clinical data were collected
including; sex, age, site of sample as well as departments in-
volved. Further processing of the isolates was performed in
the Microbiology laboratories of the College of Pharmacy,
King Saud University.
2.2. Conﬁrming the identity of the strains
All isolates of Candida spp. were identiﬁed using standard
procedures based on the germ tube test, the formation of
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gar Microbiology, Paris, France), growth features, and the fer-
mentation and assimilation proﬁles on API 20C (BioMerieux).
Isolates were maintained in 18% (v/v) glycerol at 80 C. For
further analysis, strains were ﬁrst transferred from stock
cultures onto YEPD plates (1% yeast extract, 2% Bacto
peptone, 2% D-glucose, 1.5% agar) and incubated at 37 C.
These fresh cultures were further prepared for bioﬁlm quanti-
ﬁcation, Minimum Inhibitory concentration (MIC) and
bioﬁlm eradication as well as QPCR. Candida albicans
(C. albicans) ATCC 90028 and Candida parapsilosis ATCC
96142 served as controls in each experiment.
2.3. Bioﬁlm formation and evaluation
A loopful of actively growing cells was transferred to a sterile
Yeast Nitrogen Base (YNB) broth (Difco Laboratories) con-
taining 0.9% D-glucose. After incubation at 37 C for 24 h with
shaking, the cells were centrifuged and washed twice with
0.5 ml phosphate buffer saline (PBS) by vortexing and centri-
fuging at 5000g for 5 min. The washed cells were then resus-
pended in 1 ml YNB broth. Optical density of cells was
determined for each suspension (Ultraspec 2100 Pro spectro-
photometer, BioChrom) and adjusted to a ﬁnal OD 600 value
of 1 with YNB broth (2.5–5 · 106CFU). Thereafter, 100 ll of
the suspensions was deposited in 96-well plates and incubated
at 37 C for 48 h without shaking. Bioﬁlm was stained with
0.4% (w/v) crystal violet and quantiﬁed at 590 nm after solu-
bilization with 95% ethanol. The experiment was performed
in triplicates. OD at 590 nm of the blanks, which only con-
tained Yeast Nitrogen Base broth without inoculums, were
subtracted from the values of each well of the samples (Baillie
and Douglas, 1998, 1999; Ramage et al., 2001).2.3.1. Bioﬁlm calculation
The optical density (OD) of each strain was obtained by the
arithmetic mean of the absorbance of three wells and this value
was compared with the mean absorbance of negative controls
(ODnc). The following classiﬁcation was used for the determi-
nation of bioﬁlm formation: no bioﬁlm production
(ODs = ODnc), weak bioﬁlm production (ODnc < ODsP
2ODnc), moderate bioﬁlm production (2ODnc < ODsP
4ODnc) and strong bioﬁlm production (4ODnc < ODs)
(Rodrigues et al., 2010).2.4. MIC of the Candida strains and bioﬁlm treatment
2.4.1. Susceptibility testing
MICs of amphotericin B (AMB), ﬂuconazole (FLC) and voric-
onazole (VOC), were determined for all isolates using the mic-
rodilution broth procedure recommended by the National
Committee for Clinical Laboratory Standards (2002) [recently
known as Clinical and Laboratory Standards Institute, CLSI].
MIC testing of AMB, FLC and VOC was performed in the fol-
lowing concentrations, 0.06–16 lg/ml, 0.06–128 lg/ml and
0.004–32 lg/ml, respectively, using RPMI 1640 broth with L-
glutamine, without sodium bicarbonate (Sigam, St. Louis,
MO, USA) and buffered with morpholine propanesulfonic
acid (MOPS) (Sigma, St. Louis, MO, USA). An inoculum of
0.5–2.5 · 103 CFU per ml was employed from each yield andincubated at 35 C for 48 h, and MIC end points were
calculated.2.4.2. In vitro activity of antifungal combinations against
planktonic cells
Chequerboard tests were conducted against all Candida iso-
lates (Moody, 1991). The drugs used in combinations were
AMB/FLC and AMB/VOC at the concentrations described
above MICs of individual drugs determined by visual readings
correspond to either a complete (100% for amphotericin B) or
a prominent decrease in turbidity (50% for ﬂuconazole and
voriconazol) compared with the growth control. However,
the MICs of drug combinations corresponded to prominent
(50%) growth inhibition for both dual treatments.
2.4.3. Interpretation of drug combination interaction
Drug combination interaction was classiﬁed on the basis of the
fractional inhibitory concentration index (FICi) (LaFleur
et al., 2006). The FICi was calculated by the formula: FI-
Ci = (Ac/Aa) + (Bc/Ba), where Ac and Bc are the MICs of
antifungal drugs in combination, and Aa and Ba are the MICs
of antifungal drugs A and B alone. The interaction was deﬁned
as synergistic if the FICi was <1, FICi = 1 is additive, while,
indifferent if the FICi was >1 and 64, and antagonistic if the
FICi was >4.0.
2.4.4. In vitro activity of antifungal treatment against Candida
bioﬁlms
The effects of AMB, FLC and VOC alone, and their anti-
fungal combinations were tested on two groups of selected can-
dida isolates. The ﬁrst group contains 5 strong bioﬁlm
producers (3 C. albicans, 1 Candida glabrata and 1 Candida
tropicalis) while the second one contained 5 weak bioﬁlms
forming Candida species (3 C. albicans, 1 C. glabrata and 1
C. tropicalis). Bioﬁlms were assessed using the microdilution
method and the bioﬁlms formed were detected by XTT-based
colorimetric assay (Lewis, 2010). The amount of colorimetric
change was measured using a microplate reader at A 490 nm
(model EL340, Mandel Scientiﬁc) after 1 and 24 h time period
of antifungal exposure. The changes were also observed by the
inverted microscope at the same time period. Microtitre wells
containing only YNB broth but no microbe were used as neg-
ative controls.
Moreover, 0.5 cm2 disks were cut from catheters, sterilized
and placed in 24-well tissue culture plates. Cell suspension
(80 ll) was applied to the surface of each disk, and the disks
were incubated for 1 h at 37 C for adherence. Non-adherent
organisms were removed by gentle washing with 0.15 M PBS
(5 ml), and the disks were then submerged in 1 ml of yeast
nitrogen base medium containing 50 mM glucose and incu-
bated for 48 h at 37 C (mature bioﬁlm). Catheters were then
divided into 6 groups as follows: gp 1 untreated organisms
as control, gp 2 treated with FLC alone, gp 3 treated with
VOC alone, gp 4 treated with AMB alone, gp 5 treated with
AMB/FLC and gp 6 treated with AMB/VOC. The concentra-
tion of the antimicrobials used was in very high doses, FLC
(1000 lg/ml), VOC (500 lg/ml) and AMB (32 lg/ml) and re-
duced to half in the combination form. These concentrations
were selected because they resulted in the survival of only a
small fraction of cells of each strain. After 1 h and 24 h of
58 N.H. Ibrahim et al.incubation at 35 C, half the disks of each group were
subjected to sonication (ultrasonic processor XL, NY, USA)
and counting was conducted (Hawser and Douglas, 1994).
2.5. Real time PCR
2.5.1. Preparation of settling cells for extraction
They were prepared as mentioned above, on the surface of
catheter disks. Thereafter, settling cells were removed by
sonication and centrifugation and harvested at 1 and 24 h time
periods for extraction.
2.5.2. RNA extraction cDNA formation by reverse transcriptase
Total RNA from bioﬁlm populations was isolated using the
RiboPure yeast kit (Ambion, Inc.) according to the manufac-
turer’s instructions. RNA concentrations and purity were
determined by measuring the absorbance at 260 and 280 nm
(ND-1000 spectrophotometer, NanoDrop Technologies).
Equal amounts of RNA (3 lg in 20 ll reactions) were reverse
transcribed with oligo (dT) primers using the Superscript
reverse transcriptase II (Invitrogen).
2.5.3. Quantitative PCR (QPCR) using the listed primers
Sequences of C. albicans genes were downloaded from the
Candida Genome Database using Omiga (version 2.0) software
(Table 1). Primer3 software (65) was used to design primers for
quantitative RT-PCR. The optimal conditions for choosing
efﬁcient primers included: biasing the primers toward the 30
end of the gene, restricting the amplicon size to between 50
and 200 base pairs, maintaining the GC content of the primers
at a range of 40–60%, and keeping the difference in melting
temperature between the two primers below 1 C.
Two housekeeping genes were employed in the current
investigation, the ACT1, actin producing gene, and EFB1,
translation elongation factor EF-1 beta gene. The studied
genes included CDR1, ABC membrane transporter involved
in active efﬂux of a variety of components including antifungal
agents, KRE1 gene expected producer of glycosyl phosphati-
dyl inositol, an anchor protein with a role in b-1,6-glucan bio-
synthesis, and SKN1 N-glycosylated type II membrane protein
producer with a predicted role in b-1,6-glucan biosynthesis.
2.5.4. Quantitative RT-PCR protocol
Each PCR cocktail contained the following: 1· 20 mM
Tris–HCl (pH 8.3) buffer, 50 mM KCl, 3 mM MgCl2,Table 1 The selected genes chosen for transcript analysis using qua
Gene symbol Orientation Sequence (50–30)
ACT1 Forward TTTCATCTTCT
Reverse ATGGGATGAA
EFB1 Forward GAAGGCTGCT
Reverse ACCCCAAGTC
CDR1 Forward CAGCAACCAT
Reverse GTAGCCAAAT
KRE1 Forward CCTTGCGGCA
Reverse GCATCAGTAC
SKN1 Forward CCCTGAAATT
Reverse CATAAGGAGC0.3 lM forward primer, 0.3 lM reverse primer, 1· additive re-
agent (0.2 mg/ml bovine serum albumin, 150 mM trehalose,
and 0.2% Tween-20), 0.25· SYBR green, 1.5 ll FastStart
Taq polymerase, a 200 lM concentration of each deoxynucle-
oside triphosphate, 2 ll cDNA, and H2O to bring the ﬁnal vol-
ume to 25 ll (LightCycler FastStart DNA MasterPLUS
SYBR Green I, Roche). The cDNA was ampliﬁed according
to the following steps: (i)95 C for 2 min, (ii) 95 C for 12 s,
(iii) 58–63 C for 15 s, (iv) 72 C for 20 s, and (v) 80 C for
6 s to detect SYBR green (nonspeciﬁc products melt at 80 C
and therefore were not detected). Steps ii–v were repeated
for 40 cycles, and at the end of the last cycle the temperature
was increased at 0.2 C/s from 60 to 95 C to produce a melt-
ing curve. Smart Cycler software calculated the corresponding
cycle threshold (CT) values for a threshold ﬂuorescence of 30.
All samples had RNA obtained from three independent
experiments. To avoid variation between runs, samples of all
populations were run simultaneously for each gene. Relative
quantiﬁcation of gene expression was performed using the
comparative CT method (sequence detection systems chemistry
guide; Light Cycler version 2, Software 4.1, Roche). The
most stable housekeeping genes, EFB1 and ACT1 (Beggs
et al., 2004), across the sample states were chosen using the sta-
tistical technique described by Vandesompele et al. (2002). The
internal normalization factor was the geometric mean of the
stable housekeeping genes (Vandesompele et al., 2002). The
propagated standard error of a set of triplicate samples was
estimated using the differential equation of Gauss as described
by Muller et al. (2002).
2.6. . Statistical analysis
Each experiment was performed in duplicate, and repeated at
least three times on different days. For the growth inhibition
assay the arithmetic mean and standard error obtained on
three different occasions were calculated. Signiﬁcance of differ-
ence (P 6 0.05) was assessed using the Mann–Whitney U-test.
3. Results
The current study included 49 candida isolates, collected from
different clinical specimens in the King Khalid Hospital,
Microbiology Laboratory, Riyadh, Saudi Arabia. Ages of
the patients included in the study ranged between 1 and
93 years, with a mean of 47.5 ± 22.6 years. There were 39
females representing 79.6% of the cases and 10 malesntitative RT-PCR.
Concentration (nM)
GTATCAGAGGAACTTATTT 300
TCATCAAACAAG AG 300
AAAGGTCCAAA 300
AAACCTTCCA 300
GGGTCAATTATG 300
TGGCAGCATTATC 300
GATAAAACGT 300
CTGTGACCCATACT 300
GATGCATTGGA 300
AACTTGTAATGATTGAG 300
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discharge representing 40.8% (20 samples) followed by respira-
tory tract infection in 28.6% (14 samples), urinary tract infec-
tion in 24.5% and blood borne infections (BBI) only in 6.1%
of the patients.
The most isolated organism was C. albicans (65.3%) fol-
lowed by C. tropicalis and C. glabrata found in 16.3% each,
as well as, Candida krusei which was found only in one case
representing 2%. In the present investigation, 77.6% of strains
were bioﬁlm formers (47.4% strong, 21% moderate, and
31.5% weak bioﬁlm formers). There were no signiﬁcant differ-
ences (p value > 0.05) found relating bioﬁlm formation to the
site of sample collection (Fig. 1). Moreover, there was no de-
tected relationship between the degree of bioﬁlm formation
and the ability of the organisms to show resistance or type
of species examined (Fig. 2).
As assessed by the broth microdilution method, the most
active antifungal tested was AMB, with sensitivity of 87.8%
of the examined yields, followed by VOC in 77.6%, while,
the least active was FLC found active in 67.3%. They exhibited
MIC50 and MIC90 of 0.03, 0.125 lg/ml for AMB, 0.5, 8 lg/ml
in VOC and 2, P128 lg/ml for FLC, respectively (Tables 2
and 3). Moreover, C. albicans isolates showed lower rate of
resistance than the Non- C. albicans isolates (P 6 0.05).
In addition, chequerboard study for the drug combination
was conducted to all isolates and FICi values were calculated.
Seventeen isolates (34.7%) showed antagonistic reaction with
AMB/FLC combination (FIC ranged from 5 to 44). On the
other hand, 18.4% of studied strains showed antagonistic reac-
tion with AMB/VOC combination at FIC range of 4.2–18.5.
Both combinations were most antagonistic against C. albicans
isolates rather than the Non-C. albicans strains. The synergism
was more evident with AMB/VOC combination than with
AMB/FLC (32.7% vs 12.2%, respectively) (Table 4, Fig. 3).
The mature bioﬁlms from the ten selected isolates were
found resistant to FLC and no signiﬁcant inhibition wasFigure 1 Distribution of isolates’ bioﬁlmobtained even at very high concentration (i.e. 1000 lg/ml).
Also, VOC and AMB concentration required to inhibit bioﬁlm
formation was 16–250 fold higher than the MIC for plank-
tonic. Interestingly, when high antifungal concentrations were
administered simultaneously in combinations; FLC (500 lg/
ml), VOC (250 lg/ml) and AMB (16 lg/ml) showed signiﬁcant
reduction when compared with the untreated controls
(p value 6 0.01). Furthermore, they revealed to be consider-
ably more effective than using FLC alone (p value 6 0.05).
Nevertheless, though reduction was more in combination
forms, they did not show signiﬁcance when compared to either
VOC or AMB when used alone. These results were also con-
ﬁrmed by using XTT assay and observing bioﬁlms under the
inverted microscope (Figs. 4 and 5 and Table 5).
High doses of the antifungals were employed to assess the
effect on mature bioﬁlms and the correlation of antifungal
exposure time on the persisters’ selected gene expression.
Marked over expression of SKN1 was noticed among the
mature bioﬁlms treated with AMB after 1 h of exposure
(p 6 0.05), and its expression was even more sharply induced
after 24 h (p 6 0.01). Furthermore, KRE1 was also signiﬁ-
cantly upregulated after 1 h and 24 h time periods
(p< 0.05). In the same context, both combinations exhibited
similar SKN1 over expression, even steeper, though the dose
of AMB used was reduced to half.
Surprisingly, no statistically signiﬁcant over expression of
CDR1 (p> 0.05), gene encoding efﬂux pumps, was observed
in bioﬁlms after exposure to high doses of FLC, VOC or any
of the combinations used (Table 6).
4. Discussion
In the last two decades, Candida infections have increased dis-
proportionately as a result of the increased number of compro-
mised host populations, such as patients with AIDS, diabetes
and various cancers, as well as organ-transplant recipientsstrength among different sample sites.
Figure 2 Distribution of isolates’ bioﬁlm strength among different Candida species examined.
Table 2 Antifungal susceptibility results (percent) of Candida isolates.
C. albicans C. tropicalis C. glabrata C. krusei Total
(n= 32) (n= 8) (%) (n= 8) (%) (n= 1) (%) (n= 49) (%)
FLC R 5 (15.6%) 5 (62.5%) 3 (37.5%) 1 (100%) 14 (28.6%)
I 1 (3.1%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 2 (4.1%)
S 26 (81.3%)* 3 (37.5%) 4 (50%) 0 (0.0%) 33 (67.3%)
VOC R 3 (9.4%) 2 (25%) 3 (37.5%) 1 (100%) 9 (18.3%)
I 0 (0.0%) 1 (12.5%) 1 (12.5%) 0 (0.0%) 2 (4.1%)
S 29 (90.6%)* 5 (62.5%) 4 (50%) 0 (0.0%) 38 (77.6%)
AMB R 1 (3.1%) 1 (12.5) 1 (2.5) 0 (0.0) 3 (6.1)
I 0 (0.0%) 1 (12.5) 1 (25) 0 (0.0) 3 (6.1)
S 31 (96.9%)* 7 (75) 6 (62.5) 1 (100) 43 (87.8)
* p value 6 0.05.
60 N.H. Ibrahim et al.(Beck-Sague´ and Jarvis, 1993; Wisplinghoff et al., 2004). The
number of drug-resistant Candida strains has also increased
dramatically owing to the increased use of antifungal agents.
The expression of drug-resistance genes as a mechanism by
which Candida acquires drug resistance is a well-known phe-
nomenon in the planktonic mode of growth of this fungus.
In the present study, we examined the regulation of set ofTable 3 MICs of the selected antifungals among the tested
isolates.
Antifungals (lg/ml) MIC50 MIC90 MIC range MIC mean
FLC 2 P128 0.125–P128 14.67
VOC 0.5 8 0.03–P16 0.298
AMB 0.03 0.125 0.03–P8 0.25genes’ transcription associated with drug resistance in Candida
spp.-induced mature bioﬁlms (after 48 h), and when mature
bioﬁlms were exposed to high dose of antifungals.
In the present study, 49 Candida isolates were collected
from different clinical specimens. Females represented
(79.6%) majority of cases; as, the most frequent specimens
were vaginal discharge representing 40.8% (20 samples) of
the cases. Most of these patients were diabetics (43.6%) admit-
ted for complications of diabetes mellitus (DM), followed by
pregnant females admitted for antenatal care (20.5%). This
was consistent with Nyirjesy and Sobel (2013) who identiﬁed
DM and pregnancy as important risk factors of Candida
spp. genital infections and determining C. albicans as the pre-
dominant isolated pathogen in their study. Moreover, Emam
et al. (2012) reported C. albicans as a predominant species iso-
lated from pregnant women and non-pregnant women with
vulvovaginitis.
Figure 3 Fractional inhibitory concentration (FIC) indices among the studied strains.
Table 4 Fractional inhibitory concentration (FIC) indices of AMB/FLC and AMB/VOC combinations against candida isolates.
Combined antibiotics tested FIC indices
Synergistic reaction Additive reaction Indiﬀerent reaction Antagonistic reaction
(FIC < 1) (FIC = 1) (1 > FIC 6 4) (FIC > 4)
% (No) FIC range % (No) FIC % (No) FIC range % (No) FIC range
AMB/FLC 12.2% (6) 43.5% (20) 12.2% (6) 34.7% (17)
(0.1–0.4) (1) (1.4–1.7) (5–44)
AMB/VOC 32.7% (16) 36.7% (18) 12.2% (6) 18.4% (9)
(0.04–0.4) (1) (1.2–1.8) (4.2–18.5)
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isolated in 28.6% of cases (14 samples), urinary tract infection
in 24.5% and blood borne infections (BBI) only in 6.1% of the
patients. Moreover, the most isolated organism was C. albicans
(65.3%) followed by C. tropicalis and C. glabrata found in
16.3% each. These results were comparable to a study done
in Turkey by Ece et al. (2012), who found that C. albicans
(38.6%) and C. tropicalis (13.9%) were the most prevalent iso-
lates, however, the most prevalent specimens were from UTI
unlike the present ﬁndings. The studies made in Saudi Arabia
were few and addressing mostly invasive candidal infections,
nevertheless, all of these investigations indicated the predomi-
nance of C. albicans and C. tropicalis (Al-Jasser and Elkhizzi,
2004; Al-Tawﬁq, 2007; Mohamed and Al-Ahmadey, 2013).
The present ﬁndings provided evidence that 77.6% of the
isolated strains were bioﬁlm formers. There were no signiﬁcant
difference (p value > 0.05) found related to the site of sample
collection (Fig. 1) or type of species examined (Fig. 2). The
studies done in this context showed contradicting ﬁndings.
While, Mohamed and Al-Ahmadey (2013) found that bioﬁlm
formation was more prevalent among Non-C. albicans clinical
isolates, Kuhn et al. (2002a) results showed that C. albicans
produce quantitatively more bioﬁlm than other Candida spp.
These contradictions may be due to the difference in sample
size and methods of bioﬁlm detection. Moreover, these studies
found that BBI isolates were more bioﬁlm formers than others;this was not evident in the current ﬁndings due to the small
sample size of BBI isolates.
In vitro susceptibility results of 49 Candida isolates against
amphotericin B, ﬂuconazole and voriconazole was determined
by the broth microdilution method. The most active anti-
fungal tested was AMB with sensitivity of 87.8% of the
examined yields, followed by VOC in 77.6%, while, the least
active was FLC found active in 67.3%. They exhibited MIC50
and MIC90 of 0.03, 0.125 lg/ml for AMB, 0.5, 8 lg/ml in
VOC and 2, P128 lg/ml for FLC, respectively (Tables 2
and 3). Moreover, C. albicans showed lower rate of resistance
than the Non-C. albicans isolates (P 6 0.05). Similar ﬁndings
were reached by several studies done in Saudi Arabia, Egypt
and Kuwait, they found that AMB was the most active anti-
fungal against candida isolates. Voriconazole, though similar
in mode of action to ﬂuconazole, showed activity against
FLC resistant yields and could be used against them. More-
over, they found C. albicans to be more sensitive than the
Non-C. albicans isolates, which was consistent with the pres-
ent results (Mokaddas et al., 2007; Helmi, 2009; Mohamed
and Al-Ahmadey, 2013). However, the rate of resistance
was noticed to be raised in the current investigation, this
may be explained by the widespread use of antifungal drugs
that could differ from one facility to another, long-term use
of suppressive azoles, and the use of short courses of anti-
fungal drugs (Ng et al., 2000).
Figure 4 Reduction Chart of ten selected isolates at 1 and 24 time periods per hour. The values are expressed in maximum, minimum
and average % of bioﬁlm reduction by XTT assay.
Figure 5 Candida spp. under inverted microscope · 200. Gp1: control strain after 48 h, Gp2: effect of FLC alone on settling cells after
24 h exposure, Gp3: effect of VOC alone, Gp4: effect of AMB alone, Gp5: effect of AMB/FLC, Gp6: effect of AMB/VOC.
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showed antagonistic reaction in 34.7% of the isolates against
AMB/FLC combination, while, 18.4% of studied strains
showed antagonistic reaction with AMB/VOC. Both combina-
tions revealed to be most antagonistic against C. albicans iso-
lates rather than the Non-C. albicans strains. The synergism
was more evident with AMB/VOC combination than with
AMB/FLC (32.7% vs 12.2%, respectively) (Table 4, Fig. 3).
This relatively high antagonistic effect between azoles and
poleynes was demonstrated by many earlier studies (Petrouand Rogers, 1991; Martin et al., 1994; Lignell et al., 2011). The-
oretically, the depletion of ergosterol in the cell membrane of
fungi by ﬂuconazole would antagonize the binding and conse-
quent antifungal activity, of amphotericin B. However, this
may be more evident on consequent administration of azoles
followed by AMB rather than the simultaneous administration.
Antifungal combination approach against the planktonic
form of Candida has been studied and was found promising;
however, only limited studies are available on bioﬁlms (Bach-
mann et al., 2003; Uppuluri et al., 2008; Tobudic et al., 2010a).
Table 5 Average number of sessile organisms (after 48 h – mature bioﬁlm) among the ten selected Candida isolates (CFU/disk) before
and after treatment.
Sample
No
Untreated
disks (gp1)
Treated
with
FLC(gp 2)
Treated
with
VOC (gp 3)
Treated
with
AMB (gp 4)
Treated
with
FLU/AMB (gp 5)
Treated
with
VOC/AMB (gp 6)
After 48 h 1 h 24 h 1 h 24 h 1 h* 24 h*,a 1 h* 24 h**,a 1 h**,a 24 h**,a
5 3.3 ± 0.3 3 ± 0.3 3 ± 0.6 3 ± 0.5 2.1 ± 0.3 1.2 ± 0.6 1 ± 0.5 1.3 ± 0.3 1.2 ± 0.6 1 ± 0.5 1 ± 0.9
2 3.6 ± 0.4 3.6 ± 0.5 3.5 ± 0.4 3.2 ± 0.7 3.1 ± 0.4 1.6 ± 0.3 1.3 ± 0.3 1.7 ± 0.4 1.4 ± 0.5 1.3 ± 0.7 1.5 ± 0.3
36 3.6 ± 0.5 3.3 ± 0.4 3.3 ± 0.3 3 ± 0.3 3.1 ± 0.6 1.5 ± 0.3 1.5 ± 0.4 1.6 ± 0.3 1.2 ± 0.6 1.4 ± 0.7 1 ± 0.5
4 3.8 ± 0.6 3.5 ± 0.3 3.5 ± 0.4 3.3 ± 0.2 3 ± 0.4 1.7 ± 0.4 1.5 ± 0.2 1.7 ± 0.2 1.3 ± 0.4 1.4 ± 0.2 1.2 ± 0.3
15 4.2 ± 0.9 4.1 ± 0.7 4 ± 0.4 3.9 ± 0.5 3.5 ± 0.4 2.1 ± 0.6 2 ± 0.9 2 ± 0.4 1.8 ± 0.4 2 ± 0.4 1.7 ± 0.4
6 5 ± 0.3 5 ± 0.3 4.6 ± 0.7 5 ± 0.2 4.5 ± 0.4 3.2 ± 0.4 3 ± 0.7 3.2 ± 0.4 3.1 ± 0.4 2.8 ± 0.7 2.9 ± 0.5
27 5.4 ± 0.3 5.3 ± 0.4 5.1 ± 0.4 5.1 ± 0.3 5 ± 0.6 3.4 ± 0.4 3.2 ± 0.4 3.4 ± 0.6 3 ± 0.4 3.2 ± 0.7 2.8 ± 0.3
18 6.3 ± 0.4 6.1 ± 0.3 6 ± 0.7 6 ± 0.2 5.8 ± 0.2 4.5 ± 0.5 4.3 ± 0.3 4.5 ± 0.4 4.3 ± 0.9 4.2 ± 0.4 4.1 ± 0.9
9 6.5 ± 0.3 6.4 ± 0.4 6.4 ± 0.4 6 ± 0.3 6.2 ± 0.4 4.8 ± 0.2 4.5 ± 0.4 4.2 ± 0.6 4 ± 0.2 4.2 ± 0.2 4 ± 0.7
10 6.5 ± 0.4 6.3 ± 0.2 6.2 ± 0.4 6 ± 0.6 5 ± 0.4 4 ± 0.2 3.8 ± 0.4 4 ± 0.7 3.5 ± 0.6 4.2 ± 0.4 3.8 ± 0.4
Statistically signiﬁcant difference in settling organism’s CFU between untreated and treated bioﬁlms.
Statistically signiﬁcant difference in settling organism’s CFU between treated bioﬁlms and FLC treated disks.
* P 6 0.05 compared with untreated controls.
** P 6 0.01 compared with untreated controls.
a P 6 0.05 compared with ﬂuconazole treated disks in similar time periods.
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on bioﬁlm models. In the present study, we sought to deter-
mine whether the mature bioﬁlms will be affected by high dose
of antifungal agents and whether this anti-bioﬁlm activity is
dependent on exposure time alone and in combinations.
Thus, ten selected isolates’ mature bioﬁlms formed on cath-
eter disks were exposed to FLC at very high concentration (i.e.
1000 lg/ml). Also, VOR and AMB in concentration of 500 and
32 lg/ml, respectively, were employed. These results were also
conﬁrmed by using XTT assay and observing bioﬁlms under
the inverted microscope (Figs. 4 and 5 and Table 5). Treatment
of mature bioﬁlms for 1 and 24 h indicated the high resistance
against FLC even after 24 h of exposure (p valueP 0.05). VOC
though had better results than FLC but it did not reach signif-
icance. Nevertheless, AMB showed signiﬁcant results after 24 h
of exposure (p value 6 0.05). These results were comparable to
the ﬁndings of several studies, which indicated that mature bio-
ﬁlms are tolerant to high doses of FLC and conﬁrmed that the
longer exposure time had no signiﬁcant effect on their inhibi-
tion (Hawser and Douglas, 1995; Chandra et al., 2001; RamageTable 6 Average gene expression levels of mature (48 h) candid
alone1000 lg/ml, VOC alone 500 lg/ml and AMB alone 32 lg/ml) an
16/250 lg/ml).
Treated
with FLC (gp 2)
Treated
with VOC (gp 3)
Treated
with AMB (g
1 h 24 h 1 h 24 h 1 h
CDR1 1 ± 0.4 1.6 ± 1 1.5 ± 0.5 1 ± 0.3 ND
KRE1 1.4 ± 0.4 1.9 ± 0.6 1.8 ± 0.4 2 ± 0.3 5.2 ± 2.2*
SKN1 1.3 ± 0.3 3.3 ± 0.6 2.3 ± 0.6 3.7 ± 1.6 14.3 ± 3.4*
Statistically signiﬁcant difference in gene expression between bioﬁlms trea
Gene expression levels (fold up-or down regulation) were designated with
expression in untreated bioﬁlms.
* p 6 0.05.
** p 6 0.01.et al., 2002; Mukherjee et al., 2003; Nailis et al., 2010). More-
over, comparable results were found with the use of 32 lg/ml
AMB on mature bioﬁlms by these same studies, however, the
rate of inhibition was found to reach 99% unlike the present
study. This may be because of the difference in the age of the
mature bioﬁlms. Several studies had also conﬁrmed the lack
of voriconazole activity against pre-formed mature Candida
bioﬁlms, as reported by Kuhn et al. (2002b), Katragkou et al.
(2008) and Valentin et al. (2012).
Interestingly, when high antifungal concentrations were
administered simultaneously in combinations using half the
doses used before [(FLC (500 lg/ml), VOC (250 lg/ml) and
AMB (16 lg/ml)], they showed signiﬁcant reduction when
compared with the untreated controls (p value 6 0.01). More-
over, they also revealed to be considerably more effective than
using FLC alone (p value 6 0.05). Nevertheless, though reduc-
tion was more in combination forms, they did not show signif-
icance when compared to either VOC or AMB when used
alone. Similar ﬁndings were reached by other studies, though
they were using a different azole, posaconazole, the authorsa bioﬁlms after exposure to high doses of antifungal (FLC
d their combinations (AMB/FLC 16/500 lg/ml) and (AMB/VOC
p 4)
Treated
with AMB/FLC (gp 5)
Treated
with AMB/VOC (gp 6)
24 h 1 h 24 h 1 h 24 h
1.3 ± 0.8 1.7 ± 0.3 ND 1.6 ± 1.2 1.2 ± 0.4
3.3 ± 1.3* 4.3 ± 1.3* 2.4 ± 1.7 5.3 ± 1.3* 3.3 ± 1.8
23.5 ± 6.2** 9.3 ± 3.5* 33.3 ± 3.5** 7.3 ± 1.3* 35.3 ± 2.4**
ted with antifungal drugs and untreated bioﬁlms.
the expression of a gene in bioﬁlms antifungal treated compared to its
64 N.H. Ibrahim et al.demonstrated higher susceptibility when bioﬁlms were treated
with a combination of amphotericin B and posaconazole than
when treated with single drugs (Martinez and Fries, 2010;
Tobudic et al., 2010b).
Persister cells are now known as an important mechanism of
resistance in chronic infections and they have gathered great
attention recently in the context of fungal bioﬁlms’ resistance
(Bink et al., 2011; Ramage et al., 2012). In the current study,
high doses of the antifungals were employed to assess the cor-
relation of antifungal exposure time on the persisters’ selected
gene expression. Marked over expression of SKN1 was noticed
among the mature bioﬁlms treated with AMB after 1 h of expo-
sure, and its expression was even more sharply induced after
24 h. Furthermore, KRE1 was also signiﬁcantly up-regulated
after 1 h and 24 h time periods (p< 0.05) (Table 6). In the same
context, both combinations exhibited similar SKN1 over
expression, even steeper, though the dose of AMB used was re-
duced to half. Exposure of bioﬁlms to high doses of AMB,
alone or in combinations, resulted in the survival of a small
number of very resistant cells, and these persisters seemed to ex-
hibit high expression levels of SKN1 (and, to a lesser extent,
KRE1). This was found consistent with the results of Nailis
et al. (2010), who found AMB to induce similar outcomes in
the persisters. On the other hand, Khot et al. (2006) demon-
strated that SKN1 and KRE1 were highly up-regulated in bio-
ﬁlms in the absence of AMB. Overexpression of SKN1 and
KRE1 suggests changes in cell wall maintenance, which, in
turn, could explain the high resistance of bioﬁlms toward
AMB (Gale, 1986; Liu et al., 2005). Therefore, overexpression
of both genes could be responsible for the resistance phenotype
of persisters in the presence of high doses of AMB, alone or in
combinations, on one hand, and also for the intrinsic resistance
of bioﬁlms in the absence of AMB on the other hand.
Surprisingly, no statistically signiﬁcant over expression of
CDR1, gene encoding efﬂux pumps was observed in bioﬁlms
after exposure to high doses of FLC, VOC or any of the com-
binations used (Table 6). Similar results were obtained by Nai-
lis et al. (2010) after exposure of persisters to high doses of
FLC. In the same context, comparable ﬁndings were noticed
after treatment of planktonic cells with itraconazole (De Back-
er et al., 2001). However, when planktonic cells were exposed
to FLC, upregulation of CDR1 was observed (Herna´ez
et al., 1998). This conﬁrms the difference in gene expression be-
tween persisters in bioﬁlm setting and planktonic cells.5. Conclusion
To sum it up, the current study has demonstrated that azole/
AMB combinations showed relatively high antagonistic reac-
tion against Candida spp. in the planktonic model. However,
these combinations were signiﬁcantly effective against mature
bioﬁlms, in high doses, when compared with control strains
(p value 6 0.01) or the use of FLC alone (p value 6 0.05).
Treatment of bioﬁlms with high doses of AMB, alone or in
combination, resulted in upregulation of genes encoding pro-
teins involved in b-1,6-glucan biosynthesis (SKN1, KRE1).
Transcriptional changes in sessile Candida cells in the presence
of AMB suggest upregulation of the associated biosynthetic
pathways, thereby contributing to a resistant bioﬁlm pheno-
type. Interestingly, though high resistance to azoles was quite
obvious by Candida bioﬁlms, exposure to azoles in high dosesdid not cause upregulation of genes encoding efﬂux pumps
(CDR1) or even in the non-treated bioﬁlm setting. Therefore,
bioﬁlms should be studied as a separate entity that differs from
their planktonic models. Further research is recommended to
provide more data about the molecular mechanisms underly-
ing the bioﬁlm resistance especially to azoles.Acknowledgments
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